While silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway (37). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.